Highlights by María Natalia Gandur Quiroga from ASCO GU25

The 2025 ASCO Genitourinary (GU) Cancers Symposium takes place from February 13 to 15, featuring interactive sessions focused on cutting-edge research, multidisciplinary expertise, and evidence-based practices in GU cancer care. ASCO, the American Society for Radiation Oncology, and the Society of Urologic Oncology cosponsor the symposium.

María Natalia Gandur Quiroga, Chief of the Division of Genitourinary Medical Oncology at the Angel H. Roffo Oncology Institute, shared some insights from the Symposium:

“PORTOS in Prostate Cancer”

“PORTOS in Prostate Cancer Presented by Shuang (George) Zhao, MD.

PORTOS (Prostate Cancer Radiation Therapy Outcomes Score) predicts response to radiotherapy:

• Predicts salvage dose response in SAKK 09/10
• Predicts definitive dose response in NRG/RTOG 0126
• Associated with hypoxia and immune response

Key insights:

• Higher PORTOS – Better response to dose escalation
• Lower PORTOS – Higher risk of progression
• Ongoing studies on PORTOS, toxicity, ADT, and PSMA-PET.”

“An incredible night in San Francisco with Oncology Brothers at ASCO GU25”

“What an incredible night in San Francisco with Oncology Brothers at ASCO GU25!

A fantastic atmosphere of camaraderie and high-level networking, sharing knowledge on bladder cancer, prostate cancer, and kidney cancer with top experts.

• Cutting-edge discussion on mHSPC and mCRPC with Tian Zhang and Rahul Aggarwal.
• Key updates on RCC with David Braun and Elizabeth Plimack
• Innovative insights into bladder cancer with Amanda Nizam and Jonathan Rosenberg.

Huge thanks to Oncology Brothers for the outstanding organization. A spectacular kickoff for ASCO GU25!”

“Key findings on Prostate Cancer”

“Superb discussion and insightful analysis at ASCO GU25!

Advancing towards better clinical practice with key findings on Prostate Cancer.

Enriching takeaways and steps forward!

Huge thanks to all the presenters for their contributions to the field.”

“Felix Feng’s legacy in oncology is undeniable”

“I never had the honor of knowing Felix Feng personally, but his legacy in oncology is undeniable – a brilliant scientist, an inspiring mentor, and an exceptional human being.

Before the ASCO GU25 plenary, Josh Lang, Paul Nguyen, and led a heartfelt tribute in his memory.

The ASCO YIA fellowship is announced in his honor, ensuring his impact continues to inspire future generations in Prostate Cancer.”

“Amazing presentation of TALAPRO-2”

“Abstract LBA18

Amazing presentation of TALAPRO-2: TALA+ENZA vs. ENZA in 1L mCRPC (N=805)

Presented by: Neeraj Agarwal.

Key Findings (Median FU: 52.5 months)

• Median OS: 45.8 vs. 37.0 months (HR: 0.796, P=0.0155)
• HRR-deficient: HR: 0.549 (P=0.0035)
• HRR–non-deficient/unknown: HR: 0.878 (P=0.218)
• rPFS: 33.1 vs. 19.5 months (HR: 0.667, P<0.0001)
• Manageable safety, no new signals

Clinical Takeaway:

• TALA+ENZA significantly improves OS vs. ENZA alone in 1L mCRPC, reinforcing its potential as SOC.”

“Advancing PSMA-based Theranostics in mCRPC”

“Advancing PSMA-based Theranostics in mCRPC.

Presented by Danny Mena.

PSMA PET SUVmean predicts response to 177Lu-PSMA-617

• High SUVmean – Better response vs. cabazitaxel (OR 12.2)
• PSMA uptake determines therapy success

RECIP 1.0: New imaging-based response criteria for PSMA therapy

Decline in PSMA volume predicts response

Theranostics and RLT: Turning ‘cold’ tumors ‘hot’ for better immune response.”

“STAMPEDE Trial”

“Abstract 21

STAMPEDE Trial: Transdermal Estradiol (tE2) vs. LHRHa for ADT in mPCa

Key Results:

• PSA ≤0.2 ng/ml at 6 months: tE2+ARPI 61% vs. LHRHa+ARPI 61%
• PSA90 & PSA50: Comparable (tE2 95%-100%, LHRHa 93%-100%)
• Lower rates of hot flushes with tE2 (Grade 2: 5% vs. 20% LHRHa)
• Higher gynaecomastia with tE2 (Grade 1-2: 43% vs. 10% LHRHa)
• Lower hypertension rates with tE2 (5% vs. 17% LHRHa)

Conclusion: tE2 patches offer a viable ADT option, with similar efficacy and a favorable toxicity profile for QoL.”

More posts featuring María Natalia Gandur Quiroga and ASCO GU25.